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Abstract: Implementation of guidelines can improve clinical practice. The aim in this study 
was to investigate whether neurologists in Germany adhered to the national Parkinson’s   disease 
guideline. Data were obtained from a cross-sectional survey of 60 neurologists. Analyses were 
performed on 320 patients with idiopathic Parkinson’s disease with either low grades of   functional 
impairment (Hoehn and Yahr stage I) or higher grades of functional impairment (stage II–V) 
but without motor complications. The sample was divided into four groups depending on age 
and grade of functional impairment. For each group, a biometric parameter on the use of dop-
amine agonists and L-dopa was defined based on the guideline. In patients aged ,70 years, the 
recommendation to use dopamine agonists without L-dopa (parameter 1) was observed in 53% 
of patients with lower grades of functional impairment, whilst recommended use of   dopamine 
agonists in more functionally impaired patients (parameter 2) was followed to a greater extent 
(84%). In patients aged $70 years, recommendations to use L-dopa without dopamine agonists 
were adhered to in only 50% of less functionally impaired (parameter 3) and 52% of more 
functionally impaired (parameter 4) patients. In conclusion, our results indicated there was 
moderate but not full adherence to the guideline.
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Although there is currently no cure for Parkinson’s disease, a number of treatments 
exist that can ameliorate symptoms, improve quality of life, and help avoid   secondary 
complications.1 Unfortunately, the therapeutic effect of one of the mainstays of 
treatment, L-dopa, declines after several years of use and patients may develop late-
stage motor complications2 that greatly impact on their quality of life.3 These can be 
either hypokinetic (eg, “wearing off”, end-of-dose effect, dystonia) or hyperkinetic 
(eg, peak-dose dyskinesia, biphasic dyskinesia). The attempt to return patients to a 
certain degree of autonomy in mobility in their professional and daily life, especially 
in the later stages of the disease, continues to be a medical challenge associated with 
a heavy economic burden.4–6
The prevalence of Parkinson’s disease in Germany is approximately 150 cases per 
100,000 inhabitants and 1,800 cases per 100,000 among people aged over 65 years.7 
Germany therefore has the largest number of prevalent cases of Parkinson’s disease 
of any country in Europe. In 2003, the Competence Network on Parkinson’s disease 
(CNP), a German national network supported by the Federal Ministry of Education 
and Research, developed its first guideline on Parkinson’s disease according to the 
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The German Society for Neurology then published the first 
national guideline for the treatment of Parkinson’s disease 
(status as of 11.06.2003)8 based on international standards.9–11 
Germany was one of the first European countries to publish 
national guidelines as treatment standards for physicians in 
the area of Parkinson’s disease. At the same time, changes 
in health reforms within Germany that increased demand for 
higher quality and more cost-effective treatment regimes12 
also had an impact on physicians’ prescribing behaviors and 
may have influenced whether or not they followed the new 
guideline.
Germany was therefore chosen from a multinational 
survey to evaluate the awareness and knowledge of the 
German practice guideline for Parkinson’s disease among 
  neurologists. The national guideline’s treatment recom-
mendations were based on the following core principles that 
were aimed at delaying the onset of late-stage complications 
and   reducing side effects: 1) patients less than 70 years old 
should be treated with dopamine agonists without L-dopa 
(L-dopa sparing approach); 2) if required for stable and 
adequate symptom control, more impaired patients less than 
70 years old may use L-dopa in addition to dopamine agonist 
based treatment; 3) older patients and those with comorbid 
conditions should receive L-dopa, whilst the use of dop-
amine agonists should be avoided until motor complications 
occur; 4)   independent of age and treatment basis, monotherapy 
should be initiated and maintained for as long as possible until 
patients’ impairment requires more complex treatment.
If this standard is followed, individualized pharmaco-
therapy based on age, disease stage, and characteristics can 
result in an improved ongoing relief from symptoms and may 
delay the onset of long-term motor complications. Hence, 
guidelines issued by national professional   societies are 
of particular practical relevance for treating physicians 
although, to date, little information is available on whether 
or not physicians adhere to these guidelines and implement 
them in their daily practice.13–16 The objective of this study 
was therefore to investigate whether neurologists in Germany 
implement the Parkinson’s disease national guideline in their 
daily practice, as exemplified by the actual use of dopamine 
agonists and L-dopa as recommended by the German Society 
for Neurology.
Method
Data collection
Germany was chosen as part of a multinational, cross-
sectional survey that was conducted amongst neurologists 
treating patients suffering from Parkinson’s disease (Adelphi 
Group Products. Parkinson’s II Disease Specific Programmes: 
Real World Studies. Data on file. Macclesfield, UK. 2004).17 
Data was collected during QII (April–June) 2004 from a total 
of 60 neurologists who were recruited in Germany. In order 
to cover all German regions equally, nationally representative 
samples of specialists who were responsible for decisions 
regarding drug therapy and management of outpatients with 
Parkinson’s disease were randomly screened using telephone 
interviews. Only those who expected to complete at least 
10 patient records during a 2 week period were recruited; they 
were then asked to complete patient record forms for the next 
10 Parkinson’s disease patients that visited their practice. The 
details recorded included demographics, symptoms and func-
tionality, Hoehn and Yahr (H&Y) stage, consultation history, 
and drug therapy. The study was conducted in accordance 
with ESOMAR guidelines18 and ethical approval from the 
institutional review board was not required.
The 60 neurologists provided data on 608 patients 
with Parkinsonism, of whom the 451 with a diagnosis of 
idiopathic Parkinson’s disease (according to the UK Brain 
Bank Criteria)19 were taken into consideration for further 
analyses. These figures are consistent with Parkinsonism 
and Parkinson’s disease diagnosis in a community based 
sample of participants.20 Patients were divided into five 
grades according to their level of functional impairment as 
rated by the physicians: patients without functional impair-
ment (grade I), patients in H&Y stage I (grade II), patients 
in H&Y stage II–V without motor complications (grade III), 
patients with motor complications (grade IV), and patients 
in the palliative phase (grade V). Motor complications were 
defined as L-dopa-associated such as dyskinesia, dystonia, 
on-off fluctuations, and .10% off time per day. Explicit 
rules to test guideline adherence, however, could only be 
derived for patients receiving drug treatment who were 
without motor complications. This selection was manda-
tory due to the complexity of treatment regimes in patients 
with L-dopa-associated motor complications, thus making 
the rules otherwise difficult to specify. Consequently, only 
the 320 patients in grade II (n = 82) and grade III (n = 238) 
were included in the final analyses. The patients were also 
divided into those aged ,70 years (n = 191) and those 
aged $70 years (n = 129).
Assessment of guideline adherence
Adherence to the national guideline was assessed 
using a number of methods
Firstly, we defined four explicit parameters regarding the use 
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recommendation based on the four core principles. These 
parameters were used to perform precise biometric analy-
ses to quantify the qualitative principle of the guidelines 
(Table 1).
The parameters were:
•	 Parameter	1.	Patients	aged	,70 years old in grade 
II: use of dopamine agonist without L-dopa (L-dopa 
sparing approach)
•	 Parameter	2.	Patients	aged	,70 years old in grade III: 
use of any dopamine agonist as mono- or combination 
therapy
•	 Parameter	3.	Patients	aged	$70 years old in grade II: use 
of L-dopa without dopamine agonists
•	 Parameter	4.	Patients	aged	$70 years old in grade III: 
use of L-dopa without dopamine agonists
Hence, for each patient selected for the analyses, one of 
the four parameters was applicable depending on age and 
grade of functional impairment. The percentage agreement 
between the patient’s treatment and the applicable parameter 
was therefore selected as the key outcome parameter in the 
main analysis.
Secondly, adherence to the parameters was compared 
within two groups of patients classified according to the 
claimed guideline adherence by the neurologist: “guideline 
group” (patients treated according to the national guideline as 
stated by their neurologists) and the “nonguideline group” 
(patients not treated according to the national guideline as 
stated by their neurologists). Chi-square tests for contingency 
tables were performed to investigate the relative agreement 
between the guideline and nonguideline groups. If the 
requirements were not met, Fisher’s exact test was used. 
The probability criterion for rejecting the null hypotheses 
was p = 0.05.
Thirdly, further subgroup analyses were performed 
focusing on symptom severity, time since diagnosis, and 
the presence of cognitive impairment/dementia. Since 
recommendations for treatment initiation differ in patients 
with mild symptoms, drug use was analyzed according to 
physician-rated symptom severity (presence/absence of mild 
symptoms of tremor at rest, rigidity, and bradykinesia) in 
patients in grade II. Assuming that disease duration may influ-
ence therapy in more functionally impaired patients, drug use 
was also analyzed based on time since diagnosis (,5 years 
versus $5 years) in patients in grade III. The division was 
made at 5 years since many patients begin to notice a decline 
in benefit after about 5 years of dopaminergic therapy.21
Finally, prompted by one of the guideline’s core recom-
mendations on the “reluctant use of dopamine agonists in 
patients with active comorbid medical problems”, drug use 
was analyzed in patients in grades II and III according to 
the presence/absence of cognitive impairment as a symptom 
and/or dementia as a diagnosis, as rated by the physicians 
according to their clinical standards.
All statistical analyses were performed using STATA 
software (Version 9.1; Stata Corporation, College Station, 
TX).
Results
Of the 60 neurologists, 54 were office-based, five hospital-
based, and one was based in both an office and a hospital. 
Table 1 Translation of german national guideline into explicit parameters in idiopathic Parkinson’s disease (n = 451)
Without 
functional 
impairment 
(Grade I)
Lower grade of functional 
impairment without 
motor fluctuations or 
complications (Grade II)
Higher grade of functional 
impairment without motor 
fluctuations or complications 
(Grade III)
L-dopa associated 
motor fluctuations  
or complications 
(Grade IV)
Palliative 
phase 
 
(Grade V)
,70 years 
(n = 251)
Standard 
treatment
DA (monotherapy) DA (mono or combination  
therapy)
complex management (depending 
on types of motor fluctuations and 
complications) Parameter 1: % DA  
without L-dopa
Parameter 2: % DA
Alternative 
treatment
L-dopa (if risk of losing job), 
amantadine/selegiline (if mild 
symptoms)
Patients n = 5 (2.0%) n = 64 (25.5%) n = 127 (50.6%) n = 53 (21.1%) n = 2 (0.8%)
$70 years 
(n = 200)
Standard 
treatment
L-dopa (monotherapy) L-dopa (monotherapy) complex management 
(depending on types of motor 
fluctuations and complications)
Parameter 3: % L-dopa 
without DA
Parameter 4: % L-dopa  
without DA
Alternative 
treatment
amantadine/selegiline  
(if mild symptoms)
Patients n = 1 (0.5%) n = 18 (9.0%) n = 111 (55.5%) n = 60 (30.0%) n = 10 (5.0%)
Note: Shaded area: patients included in analysis.
Abbreviation: DA, dopamine agonist.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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The mean number of Parkinson’s disease patients seen per 
week was 20.2 (range 14–25). The neurologists had a wide 
range of length of experience: 23% had been qualified for 
9–14 years, 37% for 15–24 years, and 30% for 25–34 years. 
All reported that they were aware of the content of the 
national treatment guidelines on Parkinson’s disease. The 
demographic characteristics of the 320 patients in grade II 
(n = 82; 56% male; mean age 63.4 years) and III (n = 238; 
55% male; mean age 68.6 years) who were included in the 
analysis are shown in Table 2.
The proportion of patients receiving dopamine agonists 
and L-dopa by age group (,70 years or $70 years) and grade 
(II or III) is shown in Table 3. Whilst in younger patients (espe-
cially in grade II) dopamine agonists were more frequently 
used than L-dopa, the opposite was true in older patients. 
Therefore, the data indicate a general trend for neurologists to 
adhere to the guideline. Figure 1 illustrates the level of adher-
ence to the four parameters; three of these parameters were 
only followed in about half of the patients. The recommen-
dation to use dopamine agonists without L-dopa in patients 
,70 years old with lower grades of functional impairment 
(parameter 1, L-dopa-sparing approach) was observed in 
only 53% of cases (n = 34). Moreover, more than a third of 
these younger patients (n = 23; 36%) were already receiving 
L-dopa and 19% (n = 12) were receiving L-dopa without 
a dopamine agonist. In patients $70 years old in grade II 
(parameter 3) or III (parameter 4), recommendations to use 
L-dopa without dopamine agonists were also only partially 
adhered to (n = 9 [50%] and n = 58 [52%], respectively).   
In contrast, the recommended use of   dopamine agonists 
(mono or combination) in more   functionally impaired 
patients aged ,70 years (parameter 2) was observed in the 
majority of cases (n = 107; 84%).
A total of 137 of the 320 patients (43%) were treated in 
accordance with the guidelines as stated by the neurologists. 
There were no statistically significant differences (Fisher’s 
exact test) between the guideline and nonguideline groups of 
patients (Figure 1). However, more neurologists who claimed 
that their patients were in the “guideline group” adhered to 
parameter 1 (n = 16 [66.7%] versus n = 18 [45.0%]). There 
was almost no difference between the two groups regarding 
adherence to parameter 2 (n = 48 [85.7%] and n = 59 [83.1%]). 
The small sample size for parameter 3 (n = 18) precluded 
further statistical interpretation. For parameter 4, adherence 
was actually slightly higher in the nonguideline group (n = 36; 
55.4%) than in the guideline group (n = 22; 47.8%).
Treatment in the patient subgroups is summarized in 
Table 4. Symptom severity appeared to have an impact on 
the choice of therapy in less functionally impaired patients 
(grade II) in both age groups: in patients aged ,70 years, 
L-dopa was less likely to be given to those with mild symp-
toms than those with more severe symptoms. Mild symptoms 
were also a predictor for the use of amantadine and mono-
amine oxidase (MAO)-B inhibitors in this age group. In 
patients aged $70 years, mild symptoms were a predictor for 
dopamine agonist and amantadine use. In more functionally 
Table 2 Patient demographics (n = 320)
Age (years)* 67.2 (9.6)
Time since diagnosis (years)* 4.1 (3.9)
hoehn and Yahr stage# 
 i  
  ii 
  iii 
  iV 
 V
 
82 (27.0%) 
144 (47.4%) 
65 (21.4%) 
12 (3.9%) 
1 (0.3%)
home circumstances (multiple responses possible) 
  Lives with partner 
  Lives alone 
  Nursing home 
  Lives with family/friends
 
228 (71.2%) 
51 (15.9%) 
4 (1.3%) 
27 (8.4%)
employment status 
  Full time employment 
  Part time employment 
  Unemployed 
  retired 
  homemaker
 
39 (12.2%) 
14 (4.4%) 
8 (2.5%) 
239 (74.7%) 
19 (5.9%)
caregiver required – professional or informal  182 (56.9%)
hospitalized due to Parkinson’s disease## 74 (24.1%)
Notes: *mean (SD); #n = 304; ##n = 307.
Table 3 Treatment received by patients (n = 320) divided into 
those aged ,70 years or $70 years, and grade ii or grade iii of 
functional impairment
Grade II  Grade III 
Patients aged ,70 years  
(n = 64)
Patients aged ,70 years   
(n = 127)
DA monotherapy 27 (42.2%) 24 (18.9%)
DA, no L-dopa 34 (53.1%) 41 (32.3%)
DA (overall) 45 (70.3%) 107 (84.3%)
L-dopa (overall) 23 (35.9%) 81 (63.8%)
L-dopa + DA 11 (17.2%) 66 (52.0%)
L-dopa, no DA 12 (18.8%) 15 (11.8%)
Patients aged $70 years 
(n = 18)
Patients aged $70 years 
(n = 111)
L-dopa monotherapy 4 (22.2%) 28 (25.2%)
L-dopa, no DA 9 (50.0%) 58 (52.3%)
DA (overall) 7 (38.9%) 49 (44.1%)
L-dopa (overall) 14 (77.8%) 102 (91.9%)
DA, no L-dopa 2 (11.1%) 5 (4.5%)
Abbreviation: DA, dopamine agonist.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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impaired patients (grade III), use of L-dopa plus dopamine 
agonist combination increased with time since diagnosis in 
those aged ,70 years, but not in those aged $70 years. The 
presence of cognitive impairment, however, did not have a 
marked effect on treatment decisions.
Discussion
Our results showed that neurologists in Germany use dop-
amine agonists and L-dopa differently in different patient 
populations, with treatment being dominated by dopamine 
agonists in younger patients and L-dopa in older patients. 
This is an initial indicator of a general adherence to the 
national guideline.
However, if the guideline is translated into strict param-
eters, as in the current study, it is apparent that neurologists 
do not adhere well to recommendations on monotherapy, 
regardless of the patient’s age and grade of functional 
impairment. For example, only around half of patients aged 
,70 years in H&Y stage I received dopamine agonists 
without L-dopa and, surprisingly, more than a third were 
already receiving L-dopa. As patients with mild symptoms 
were less likely to receive L-dopa than those with more 
severe symptoms, symptom severity might be one reason 
for early use of L-dopa. Other potential reasons may involve 
individual patient circumstances and financial considerations 
reinforced by changes in health reform since, in Germany, 
L-dopa is much cheaper than dopamine agonists. Mild 
symptoms in patients with a lower grade of functional 
impairment were a clear predictor for use of amantadine 
and the MAO-B inhibitor selegiline; these findings are in 
line with guideline recommendations. Use of the L-dopa 
plus dopamine agonist combination increased with disease 
duration and grade of functional impairment, most notably in 
younger patients. This suggests that physicians try to adhere 
to the parameter of an L-dopa-sparing approach in younger 
patients for as long as possible. In patients aged $70 years, 
Percentage of patients treated in accordance with the rule
n = 64
n = 24
n = 40
n = 127
n = 56
n = 71
n = 18
n = 11
n = 7
n = 111
n = 46
n = 65
P = 0.12
P = 0.81
 P = n.a.
 P = 0.45
Parameter
1
Parameter
2
Parameter
3
Parameter
4
02 04 0 60 80 100
Overall adherence to national guideline Guideline group Nonguideline group
Figure 1 Level of adherence to national guideline. Overall adherence and adherence in neurologists who state that they follow the guideline (“guideline group”) and those 
who do not state that they follow the guideline (“nonguideline group”).
Notes: Parameter 1. Patients ,70 years, grade ii (n = 64): use of dopamine agonist without L-dopa. Parameter 2. Patients ,70 years, grade iii (n = 127): use of any dopamine 
agonists as mono or combination therapy. Parameter 3. Patients $70 years, grade ii (n = 18): use of L-dopa without dopamine agonists. Parameter 4. Patients $70 years, 
grade iii (n = 111): use of L-dopa without dopamine agonists.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the level of adherence to L-dopa without dopamine agonists 
was similar in grades II and III, with only limited agreement 
with the guideline in both cases. Combination therapy with 
L-dopa plus dopamine agonists increased slightly with 
longer disease duration and mild symptoms, which might 
partly explain nonadherence to the recommended mono-
therapy in older patients. The small number of patients aged 
$70 years in grade II, as would be expected in Parkinson’s 
disease, means that no firm conclusions can be drawn for 
this patient subgroup.
When comparing agreement with the parameters accord-
ing to claimed guideline adherence, the differences did not 
achieve statistical significance. It therefore cannot be con-
cluded that neurologists who claimed to follow the guideline 
did indeed follow it more strictly.
As the derivation of statistically testable parameters 
from any guideline recommendation is not straightforward, 
there may be a number of methodological reasons that 
  influence the low level of agreement between the physician’s 
  treatment choice and the guideline. One possible reason 
is that the parameters cannot take into account individua-
lized therapy based on patient characteristics as is recom-
mended in the guideline. The different possible definitions 
of key variables are another potential problem. Initiation 
with and maintenance of monotherapy for as long as pos-
sible is one of the core recommendations. When translating 
the term “monotherapy” directly from the guideline, it is 
naturally linked to the L-dopa sparing approach in younger 
patients or the reluctant use of dopamine agonists in older 
or comorbid patients. However, we chose the more precise 
Table 4 Percentage use of L-dopa, dopamine agonists, amantadine, and MAO-B inhibitors in patient subgroups (n = 320)
Any 
dopamine 
agonist
Dopamine 
agonist + 
L-dopa
L-dopa Amantadine MAO-B 
inhibitor
Symptom severity – mild symptoms
,70, grade ii Yes (n = 46) 31 
(67.4%)
6  
(13.0%)
15 
(32.6%)
11 
(23.9%)
5 
(10.9%)
No (n = 18) 14 
(77.8%)
5  
(27.8%)
8 
(44.4%)
0 0
$70, grade ii Yes (n = 12) 6  
(50.0%)
4  
(33.3%)
9 
(75.0%)
4 
(33.3%)
1  
(8.3%)
No (n = 6) 1  
(16.7%)
1 
(16.7%)
5 
(83.3%)
0 1 
(16.7%)
Disease duration – time since diagnosis
,70, grade iii ,5 years 
(n = 84)
71 
(84.5%)
35 
(41.7%)
44 
(52.4%)
19 
(22.6%)
12 
(14.3%)
$5 years 
(n = 43)
36 
(83.7%)
31 
(72.1%)
37 
(86.0%)
15 
(34.9%)
10 
(23.3%)
$70, grade iii ,5 years 
(n = 71)
30 
(42.3%)
25 
(35.2%)
63 
(88.7%)
12 
(16.9%)
5 
(7.0%)
$5 years 
(n = 40)
19 
(47.5%)
19 
(47.5%)
39 
(97.5%)
15 
(37.5%)
10 
(25.0%)
Cognitive impairment
,70, grade ii Yes (n = 6) 4  
(66.7%)
1 
(16.7%)
2 
(33.3%)
1 
(16.7%)
0
No (n = 58) 41 
(70.7%)
10 
(17.2%)
21 
(36.2%)
10 
(17.2%)
5 
(8.6%)
,70, grade iii Yes (n = 16) 13 
(81.3%)
9  
(56.3%)
11 
(68.8%)
6 
(37.5%)
1 
(6.3%)
No (n = 111) 94 
(84.7%)
57 
(51.4%)
70 
(63.1%)
28 
(25.2%)
21 
(18.9%)
$70, grade ii Yes (n = 3) 0 0 3 
(100%)
0 0
No (n = 15) 7  
(46.7%)
5 
(33.3%)
11 
(73.3%)
4 
(26.7%)
2 
(13.3%)
$70, grade iii Yes (n = 26) 11 
(42.3%)
10 
(38.5%)
23 
(88.5%)
7 
(26.9%)
3 
(11.5%)
No (n = 85) 38 
(44.7%)
34 
(40.0%)
79 
(92.9%)
20 
(23.5%)
12 
(14.1%)Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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variables “dopamine agonist without L-dopa” and “L-dopa 
without dopamine agonist” to investigate accordance with 
the guideline.
Another factor that should be taken into account is 
that we divided the patients according to physician-rated 
grades of functional impairment based on H&Y stages and 
L-  dopa-associated motor complications, whilst the guideline 
does not. In particular, if maintenance of monotherapy for as 
long as possible is recommended, patients’ level of functional 
impairment must be taken into account when translating the 
guideline recommendations into explicit parameters since 
progression across H&Y stages is closely related to the dura-
tion of disease.22 Our analyses revealed that monotherapy 
was only partly followed by neurologists, independently of 
H&Y stage. In general, and particularly when giving advice 
on monotherapy, the guideline should be more precise in 
terms of functional impairment.
In the analyses, we used data from a nationwide study 
aimed at obtaining as representative a sample of real-
life Parkinson’s disease patients in Germany as possible. 
  Consequently neurologists were the focus, most of whom 
were office-based, as the majority of Parkinson’s disease 
patients in Germany are treated in this setting.2 However, as 
prescription patterns may change if patients are treated by 
general practitioners or in outpatient clinics,23,24 it might be 
of interest to investigate guideline adherence in these set-
tings, as well as in more severely ill patients at a later H&Y 
stage or those treated as in-patients. In contrast to the results 
of some other studies in which the patient population was 
restricted, for example, to members of a support group,23 
we used data from outpatients typical of those treated in 
everyday   clinical practice. Nevertheless, there may have 
been an inherent selection bias amongst the neurologists 
who took part in the study, as only those who were able to 
provide the necessary information within the required time 
frame were selected.
The 10–13 months between publication of the guideline 
and performance of the survey should have allowed suffi-
cient time to reflect the impact on clinical practice. Indeed, 
all physicians in the survey reported that they were aware of 
the content of the guideline. It is worthy of consideration that 
Parkinson’s disease guidelines are based on evidence-based 
medicine and, as guidelines take around two years to develop, 
this evidence may itself be outdated by the time the guidelines 
are published.25 Many practicing physicians would therefore 
have also already been exposed to the evidence base during 
this intervening period. We presume that the physicians were, 
as they stated, aware of current treatment practices reviewed in 
the guidelines and that this survey can therefore be considered 
of relevance.
We investigated adherence to the first guideline that 
was issued in Germany in 2003. Updates of the guideline 
were published in 2005 and 2008,26 and it is possible that 
the neurologists’ awareness of treatment guidelines might 
have   subsequently changed. Increasing concerns regarding 
adverse events associated with dopamine agonists, including 
daytime somnolence, leg edema, impulse control disorders, 
and valvular heart conditions27 may, for example, have 
influenced clinical practice since our survey was conducted 
in 2004. The current guidelines from 2008, however, still 
  follow the same core treatment recommendations, albeit being 
more restrictive in the use of ergot dopamine agonists.
Findings from a study to assess German neurologists’ 
awareness of the existence of the national guideline were 
published in 2005.13 This cross-sectional questionnaire 
was carried out using 181 neurologists in private practice. 
Surprisingly, only about half of the neurologists claimed to 
be aware of the guideline. Of these, 60% rated the guideline 
positively, although 53% reported having problems using 
it in their general practice. This suggests that implementa-
tion strategies may be necessary to improve neurologists’ 
knowledge and use of the guideline. A study into the attitudes 
and barriers to the national guideline in Germany indicated 
that lack of time and an inability to reconcile patient prefer-
ences with guideline recommendations were also important 
reasons for nonadherence.14 Previous researchers have shown 
that implementation of clinical guidelines is associated with 
a wide range of problems,28 although their adoption can 
help to improve the quality of care.29,30 There is, however, a 
paucity of data on how guideline adherence influences the 
patient’s outcome.
In conclusion, our study of German neurologists can 
be regarded as a pilot approach to translating a clinical 
guideline into distinctive parameters to evaluate guideline 
adherence of neurologists treating patients with Parkinson’s 
disease. The findings revealed that recommendations were 
only partially followed. Further research is needed into the 
reasons for nonadherence and the impact of guideline adher-
ence on therapeutic outcomes.
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